Loading stock data…
Innoviva (INVA)
$23.57+0.22 (+0.94%)
Market ClosedLast close Jun 26
Innoviva, Inc.
Historical Price
Price (Candle)
50-Day SMA
200-Day SMA
Whystock Brain
The Narrative
Innoviva, Inc. in the Healthcare sector is trading at $23.57 with a market capitalization of $1.7B. Wall Street consensus targets $35.50 (4 analysts), implying a +50.6% move over the next 12 months. The stock is currently near its 52-week high of $25.15, remaining 11.6% above its 200-day moving average. On fundamentals, Piotroski 4/9 shows mixed financial quality, Altman Z in the safe zone. The Whystock Score of 100/100 reflects bullish alignment across trend, valuation and analyst targets.
Ecosystem Influences
Sell-side targets imply +50.6% upside over 12 months
Long-term trend bullish (price vs 200-day SMA)
Macro-economic sensitivity to interest rate and inflation shifts
Quarterly Financials
| Metric (USD) | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 |
|---|---|---|---|---|---|
| Total Revenue | $97.99M↓ | $114.61M↑ | $107.80M↑ | $100.28M↑ | $88.63M |
| Gross Profit | $82.39M↓ | $101.94M↑ | $75.54M↓ | $89.69M↑ | $79.79M |
| Operating Income | $38.15M↓ | $38.99M↑ | $34.58M↓ | $48.75M↑ | $41.43M |
| Net Income | $186.59M↑ | $164.15M↑ | $89.91M↑ | $63.69M↑ | -$46.58M |
Peer Comparison
JNJUNHPFE
Fundamentals
Innoviva, Inc. operates as a biopharmaceutical company in the United States and internationally. Its royalty portfolio includes RELVAR/BREO ELLIPTA, a once-daily combination medicine consisting of a LABA, vilanterol, and an inhaled corticosteroid, an...
Market Cap
Total dollar market value of a company's outstanding shares of stock (Price * Shares).
$1.67B
P/E Ratio
Priced for growth. Investors expect sustained double-digit expansion.
-
Beta
High-beta play. Expect amplified moves vs. the broad market.
-
Div Yield
Low to zero yield. Return is entirely dependent on price appreciation.
0.00%
ROE
Elite ROE. Management converts capital into profit efficiently.
37.59%
Volume
Today's trading volume
2.83M
Recent News
Innoviva, Inc. (INVA) Launches Nortiva Bio to Advance Long-Acting Oral Drug Platform
We recently compiled a list of the 10 Most Promising Small-Cap Stocks to Buy According to Hedge Funds. Innoviva, Inc. (NASDAQ:INVA) is one of the most promising stocks on our list. TheFly reported on June 18 that INVA announced the launch of Nortiva Bio, a clinical-stage biopharmaceutical company focused on developing long-acting oral therapies through its proprietary […]
Innoviva Specialty Therapeutics (INVA) Partners With Dr. Reddy’s to Expand XACDURO Access Internationally
Innoviva Inc. (NASDAQ:INVA) is one of the most profitable undervalued stocks to invest in. On June 16, Innoviva Specialty Therapeutics entered an exclusive licensing and distribution agreement with Dr. Reddy’s Laboratories to bring XACDURO to South and Central America, the Caribbean, Russia, and the CIS region. The partnership aims to address a critical health challenge, […]
Innoviva Stock Is Up Just 10% This Past Year. Here's Why a Fund Bought $2.5 Million More
Innoviva develops respiratory pharmaceuticals through strategic partnerships and royalty agreements in the global healthcare market.
Is Innoviva (INVA) Pricing Look Compelling After Recent Share Price Softness?
Wondering whether Innoviva's current share price reflects its true worth, or if the stock might be mispriced. After some shorter term share price weakness, with the stock down 0.4% over the past week and 3.7% over the past month, Innoviva is still up 15.2% year to date and 23.0% over the last year. Those moves sit against a backdrop of ongoing attention on Innoviva's position in the pharmaceuticals space and on how investors weigh its portfolio and balance sheet against sector peers. Recent...
Innoviva, Inc. (INVA) Draws Bullish View from Cantor on Recurring Royalty Strength
Innoviva, Inc. (NASDAQ:INVA) is one of the best small-cap value stocks to buy. On April 8, Cantor Fitzgerald reiterated an Overweight rating on Innoviva Inc. (NASDAQ:INVA) and a $32 price target. The research firm remains confident about the company’s prospects, owing to the stability of its recurring royalty business that generated about $250 million in […]